INSIGHT

San Diego Biotech Companies and the NIH Funding Freeze: A Financial Impact Overview

May 26, 2026

---

If you lead a life sciences or biotech company in San Diego, the last several months have felt different. Grants that were expected are delayed. Projects that seemed fully funded are now in limbo. And the timeline for resolution remains unclear.

This is not a typical funding cycle. The federal research disruption affecting San Diego biotech companies in 2025 and 2026 is unlike anything the industry has navigated before, and it’s prompting finance leaders across Biotech Beach to reassess assumptions about cash flow, capital planning, and program prioritization.

Here’s a clear-eyed look at what’s happening and where the financial pressure is concentrating.

Two Distinct Problems Driving the Disruption

To understand the current environment, it helps to separate two related but different challenges: the policy disruption and the disbursement slowdown.

Policy Disruption

On the policy side, the federal government has made significant changes to how NIH grants are approved, categorized, and prioritized. Grants have been canceled mid-project, a practice that was virtually unheard of before 2025. Funding opportunities have been modified or closed. And the overall NIH budget trajectory remains under pressure, with the White House’s proposed FY2026 budget seeking a roughly 40% reduction and its FY2027 proposal signaling further cuts.

Disbursement Slowdown

On the disbursement side, the challenge is more immediate. Even grants that Congress has appropriated funds for are not necessarily flowing on their expected timelines. At roughly six months into the current fiscal year, only a fraction of typical cancer research funding had been distributed nationally.

In San Diego, six of the region’s most prominent research institutions saw cancer research grants drop from approximately $103 million to $87 million between FY2024 and FY2025, a 16% decline. UC San Diego, which received $46.8 million in cancer research funding last fiscal year, had received only $10.8 million at a comparable point this year.

For San Diego biotech companies, many of which rely on NIH-backed academic research at UCSD, Scripps, Salk, and Sanford Burnham Prebys to feed their innovation pipelines, this is a direct operational challenge, not a distant policy debate.

Where Financial Pressure Is Concentrating

The effects are showing up across several areas of biotech financial management simultaneously.

Cash Flow and Burn Rate

Companies that modeled predictable NIH disbursement timelines are finding themselves waiting significantly longer than anticipated. That gap puts direct pressure on burn rate and near-term operating decisions.

Workforce Planning

Research positions, postdoctoral roles, and lab staff funded through a combination of federal grants and private capital become difficult to plan around when federal funding timelines are unpredictable.

Capital Runway and Investor Conversations

Sophisticated investors are increasingly factoring NIH funding exposure into their due diligence. Federal funding exposure has become a more prominent factor in investor due diligence conversations.

R&D Program Prioritization

Constrained funding is prompting companies to make harder decisions about program sequencing and milestone prioritization.

San Diego’s Biotech Fundamentals Remain Strong

The disruption is real, but San Diego remains one of the world’s most resilient biotech ecosystems.

And the concentration of world-class institutions, from UCSD and Scripps to the Salk Institute, continues to give San Diego a structural advantage that federal funding cycles alone cannot diminish.

What the current environment is testing is not San Diego biotech’s scientific strength. It’s the financial resilience of individual companies and how they navigate a more uncertain funding landscape.